Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Sold by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky trimmed its holdings in Ironwood Pharmaceuticals (NASDAQ:IRWD) by 9.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 616,747 shares of the biotechnology company’s stock after selling 67,233 shares during the period. Teachers Retirement System of The State of Kentucky owned 0.41% of Ironwood Pharmaceuticals worth $9,245,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of IRWD. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Ironwood Pharmaceuticals by 128.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,010 shares of the biotechnology company’s stock valued at $135,000 after acquiring an additional 5,069 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management acquired a new stake in Ironwood Pharmaceuticals in the 3rd quarter valued at about $170,000. Hemenway Trust Co LLC acquired a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at about $204,000. Bailard Inc. acquired a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at about $345,000. Finally, Oppenheimer Asset Management Inc. grew its stake in Ironwood Pharmaceuticals by 30.9% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 23,405 shares of the biotechnology company’s stock valued at $369,000 after acquiring an additional 5,527 shares during the last quarter.

How to Become a New Pot Stock Millionaire

NASDAQ IRWD opened at $14.36 on Friday. The company has a debt-to-equity ratio of 40.25, a quick ratio of 4.71 and a current ratio of 4.72. The stock has a market cap of $2,245.33, a price-to-earnings ratio of -15.44 and a beta of 1.07. Ironwood Pharmaceuticals has a 1 year low of $12.89 and a 1 year high of $19.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.04. The firm had revenue of $94.20 million for the quarter, compared to the consensus estimate of $88.86 million. Ironwood Pharmaceuticals had a negative return on equity of 2,073.20% and a negative net margin of 39.20%. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.12) EPS. sell-side analysts expect that Ironwood Pharmaceuticals will post -0.46 earnings per share for the current year.

In other Ironwood Pharmaceuticals news, CFO Gina Consylman sold 3,594 shares of the business’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $14.66, for a total transaction of $52,688.04. Following the sale, the chief financial officer now owns 59,125 shares in the company, valued at approximately $866,772.50. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Mark G. Currie sold 60,000 shares of the business’s stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $15.45, for a total value of $927,000.00. Following the sale, the insider now owns 835,000 shares in the company, valued at approximately $12,900,750. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 66,728 shares of company stock worth $1,024,732. Corporate insiders own 7.63% of the company’s stock.

A number of equities research analysts recently commented on IRWD shares. ValuEngine cut shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 29th. BidaskClub cut shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 30th. Bank of America cut shares of Ironwood Pharmaceuticals from a “buy” rating to an “underperform” rating and dropped their price target for the stock from $20.00 to $15.00 in a research report on Friday, January 5th. Finally, Zacks Investment Research cut shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $17.29.

ILLEGAL ACTIVITY WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/07/ironwood-pharmaceuticals-inc-irwd-shares-sold-by-teachers-retirement-system-of-the-state-of-kentucky.html.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply